CX Institutional Has $6.05 Million Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH

CX Institutional boosted its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 220.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 263,283 shares of the company’s stock after buying an additional 181,136 shares during the period. CX Institutional owned about 0.56% of Amphastar Pharmaceuticals worth $6,045,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Signaturefd LLC increased its position in shares of Amphastar Pharmaceuticals by 147.7% in the first quarter. Signaturefd LLC now owns 872 shares of the company’s stock worth $25,000 after acquiring an additional 520 shares in the last quarter. IFP Advisors Inc acquired a new position in Amphastar Pharmaceuticals in the 1st quarter worth approximately $34,000. MassMutual Private Wealth & Trust FSB grew its position in Amphastar Pharmaceuticals by 192.8% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,262 shares of the company’s stock worth $29,000 after purchasing an additional 831 shares in the last quarter. GAMMA Investing LLC grew its position in Amphastar Pharmaceuticals by 46.6% during the 1st quarter. GAMMA Investing LLC now owns 1,333 shares of the company’s stock worth $39,000 after purchasing an additional 424 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of Amphastar Pharmaceuticals in the first quarter valued at $39,000. 65.09% of the stock is owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH stock opened at $26.36 on Friday. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $20.39 and a fifty-two week high of $53.96. The stock’s 50-day moving average is $26.70 and its two-hundred day moving average is $25.54. The company has a debt-to-equity ratio of 0.80, a current ratio of 3.29 and a quick ratio of 2.21. The firm has a market cap of $1.23 billion, a P/E ratio of 9.87 and a beta of 0.80.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on AMPH. Needham & Company LLC upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $36.00 price target on the stock in a report on Tuesday, August 12th. Piper Sandler lowered their target price on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating on the stock in a research note on Friday, August 8th. Finally, Bank of America upped their target price on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a report on Tuesday, August 26th. Two equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $31.60.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.